Consistent with the potential to predict tumor responsiveness to the combination of voruciclib and venetoclax, both U2932 and RIVA models exhibited regions of robust enhancement of cleaved caspase 3 positive (CC3+) apoptotic cells that significantly surpassed responses induced by either single agent alone (Fig. 4). The gene discussed is CASP3; the disease is neoplasm.